WuXi Biologics (Cayman) Inc
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic disc… Read more
WuXi Biologics (Cayman) Inc (WXXWY) - Total Assets
Latest total assets as of June 2025: $60.44 Billion USD
Based on the latest financial reports, WuXi Biologics (Cayman) Inc (WXXWY) holds total assets worth $60.44 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
WuXi Biologics (Cayman) Inc - Total Assets Trend (2014–2024)
This chart illustrates how WuXi Biologics (Cayman) Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
WuXi Biologics (Cayman) Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
WuXi Biologics (Cayman) Inc's total assets of $60.44 Billion consist of 41.4% current assets and 58.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.5% |
| Accounts Receivable | $5.79 Billion | 10.2% |
| Inventory | $1.52 Billion | 2.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $442.37 Million | 0.8% |
| Goodwill | $1.53 Billion | 2.7% |
Asset Composition Trend (2014–2024)
This chart illustrates how WuXi Biologics (Cayman) Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: WuXi Biologics (Cayman) Inc's current assets represent 41.4% of total assets in 2024, an increase from 36.0% in 2014.
- Cash Position: Cash and equivalents constituted 14.5% of total assets in 2024, up from 0.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 10.2% of total assets.
WuXi Biologics (Cayman) Inc Competitors by Total Assets
Key competitors of WuXi Biologics (Cayman) Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
WuXi Biologics (Cayman) Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - WuXi Biologics (Cayman) Inc generates 0.33x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, WuXi Biologics (Cayman) Inc generates $5.89 in net profit.
WuXi Biologics (Cayman) Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.88 | 2.91 | 2.96 |
| Quick Ratio | 2.69 | 2.62 | 2.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $15.96 Billion | $ 13.01 Billion | $ 6.24 Billion |
WuXi Biologics (Cayman) Inc - Advanced Valuation Insights
This section examines the relationship between WuXi Biologics (Cayman) Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.54 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 0.7% |
| Total Assets | $56.98 Billion |
| Market Capitalization | $16.07 Billion USD |
Valuation Analysis
Below Book Valuation: The market values WuXi Biologics (Cayman) Inc's assets below their book value (0.28 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: WuXi Biologics (Cayman) Inc's assets grew by 0.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for WuXi Biologics (Cayman) Inc (2014–2024)
The table below shows the annual total assets of WuXi Biologics (Cayman) Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $56.98 Billion | +0.71% |
| 2023-12-31 | $56.58 Billion | +14.15% |
| 2022-12-31 | $49.56 Billion | +12.56% |
| 2021-12-31 | $44.03 Billion | +52.03% |
| 2020-12-31 | $28.96 Billion | +64.54% |
| 2019-12-31 | $17.60 Billion | +87.39% |
| 2018-12-31 | $9.39 Billion | +93.71% |
| 2017-12-31 | $4.85 Billion | +144.28% |
| 2016-12-31 | $1.98 Billion | +46.31% |
| 2015-12-31 | $1.36 Billion | +113.10% |
| 2014-12-31 | $636.67 Million | -- |